NCT06698796View on ClinicalTrials.gov

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

PHASE3RecruitingINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

November 25, 2027

Study Completion Date

November 25, 2027

Conditions
DermatomyositisPolymyositis
Interventions
DRUG

Dazukibart

anti-interferon beta therapy

Trial Locations (9)

4000

RECRUITING

Medical Center Artmed, Plovdiv

25801

RECRUITING

Rheumatology & Pulmonary Clinic, Beckley

85306

NOT_YET_RECRUITING

AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale

100730

RECRUITING

Beijing Peking Union Medical College Hospital, Beijing

200127

RECRUITING

Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

230071

RECRUITING

Anhui Provincial Hospital, Hefei

682040

NOT_YET_RECRUITING

CHARM HEALTHCARE PRIVATE LIMITED (Previously Dr Shenoy's Care Private Limited), Ernākulam

113-8519

NOT_YET_RECRUITING

Institute of Science Tokyo Hospital, Bunkyo-ku

113-8603

NOT_YET_RECRUITING

Nippon Medical School Hospital, Bunkyo-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06698796 - A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies | Biotech Hunter | Biotech Hunter